NEW YORK (AP) — NEW YORK (AP) — Intra-Cellular Therapies Inc. (ITCI) on Thursday reported a loss of $28.6 million in its fourth quarter.

The New York-based company said it had a loss of 30 cents per share.

The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 44 cents per share.

The biopharmaceutical company posted revenue of $132.1 million in the period, missing Street forecasts. Five analysts surveyed by Zacks expected $136.3 million.

For the year, the company reported a loss of $139.7 million, or $1.46 per share. Revenue was reported as $464.4 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ITCI at https://www.zacks.com/ap/ITCI

For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights. , source Associated Press News